AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2021

May 24, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK: 0001439222
Period of Report: 2021-05-20

Reporting Person: Foster-Cheek Kaye I (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-05-20	Restricted stock unit	$	A	1585	Acquired		Common stock (1585.0)	Direct
2021-05-20	Stock options (right to buy)	$56.76	A	8888	Acquired	2031-05-20	Common stock (8888.0)	Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F2: The restricted stock units were granted on May 20, 2021. The shares underlying the stock units will vest in full on May 20, 2022. Vested shares will be delivered to the reporting person within three business days after such shares become vested

F3: This option was granted on May 20, 2021. The shares underlying this option vest as to 100% of the underlying shares on May 20, 2022.